De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort.

Authors :: Jaulent, L.
Staumont‐Sallé, D.
Tauber, M.
Paul, C.
Aubert, H.
Marchetti, A.
Sassolas, B.
Valois, A.
Nicolas, J.‐F.
Nosbaum, A.
Source :: Journal of the European Academy of Dermatology & Venereology. Apr2021, Vol. 35 Issue 4, pe296-e297. 2p.
Publication Year :: 2021
Abstract: Nevertheless, this therapeutic class can promote immune dysbalance, since two recent cases of baricitinib-induced paradoxical psoriasis have been reported.13 The mechanisms of psoriasis' development during dupilumab treatment in AD patients are unknown. Atopic dermatitis (AD) and psoriasis are T cell-mediated inflammatory diseases: a Th2-component with interleukin (IL)-4 and IL-13 production in AD, a Th17/IL-23 and TNF response in psoriasis. [Extracted from the article]

Subjects :: *ATOPIC dermatitis
*PSORIASIS
*TYPE I interferons
*PSORIATIC arthritis

Full Text Access

Tools